Bill

Bill > S1822


NJ S1822

NJ S1822
Requires performance of myeloma screening under certain circumstances.


summary

Introduced
01/09/2024
In Committee
01/09/2024
Crossed Over
Passed
Dead
01/12/2026

Introduced Session

2024-2025 Regular Session

Bill Summary

This bill requires the performance of a myeloma screening under certain circumstances. Under the bill, a licensed health care professional who performs an annual physical examination on a male patient is to include as part of that examination a screening for myeloma. Myeloma, also called multiple myeloma, is a cancer of the plasma cells. Plasma cells are white blood cells that make antibodies which protect from infection. In a case of myeloma, cancerous plasma cells accumulate in the bone marrow and overcome healthy blood cells. Rather than produce helpful antibodies, the cancer cells produce abnormal proteins that can cause complications. There are legislative findings and declarations in the bill, which include that African-American men have the highest myeloma incidence and death rates according to the American Cancer Society.

AI Summary

This bill requires the performance of a myeloma screening as part of annual physical examinations for male patients. Myeloma, also called multiple myeloma, is a type of cancer that affects plasma cells, the white blood cells responsible for producing antibodies. The bill includes legislative findings that myeloma has high incidence and death rates, particularly among African-American men, and determines it is in the public interest to mandate this screening as part of routine care for men.

Committee Categories

Health and Social Services

Sponsors (1)

Last Action

Introduced in the Senate, Referred to Senate Health, Human Services and Senior Citizens Committee (on 01/09/2024)

bill text


bill summary

Loading...

bill summary

Loading...

bill summary

Loading...